The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Markovic SN. Novel therapeutics for the treatment of metastatic melanoma. Future Oncol 2009; 5:543 - 57; http://dx.doi.org/10.2217/fon.09.15; PMID: 19450181
   PubMed Web of Science ®Google Scholar
• Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al, Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 2007; 82:490 - 513; http://dx.doi.org/10.4065/82.4.490; PMID: 17418079
   PubMed Web of Science ®Google Scholar
• Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al, Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007; 82:364 - 80; PMID: 17352373
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507 - 16; http://dx.doi.org/10.1056/NEJMoa1103782; PMID: 21639808
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al, EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117 - 26; http://dx.doi.org/10.1016/S0140-6736(08)61033-8; PMID: 18620949
   PubMed Web of Science ®Google Scholar
• Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 2006; 106:375 - 82; http://dx.doi.org/10.1002/cncr.21611; PMID: 16342250
   PubMed Web of Science ®Google Scholar
• Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer 2011; 117:1704 - 10; http://dx.doi.org/10.1002/cncr.25659; PMID: 21472717
   PubMed Web of Science ®Google Scholar
• Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 2013; 119:586 - 92; http://dx.doi.org/10.1002/cncr.27760; PMID: 22915053
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335 - 42; http://dx.doi.org/10.1056/NEJMoa032691; PMID: 15175435
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542 - 50; http://dx.doi.org/10.1056/NEJMoa061884; PMID: 17167137
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427 - 34; http://dx.doi.org/10.1056/NEJMoa021491; PMID: 12890841
   PubMed Web of Science ®Google Scholar
• Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012; 30:34 - 41; http://dx.doi.org/10.1200/JCO.2011.34.6270; PMID: 22124101
   PubMed Web of Science ®Google Scholar
• Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN, Melanoma Study Group of the Mayo Clinic Cancer Center. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009; 15:1931 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-08-1980; PMID: 19240164
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150 - 66; PMID: 9834220
   PubMed Web of Science ®Google Scholar
• Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 2007; 56:761 - 70; http://dx.doi.org/10.1007/s00262-006-0234-7; PMID: 17086423
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479; PMID: 22156613
   PubMed Web of Science ®Google Scholar
• Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105:93 - 103; http://dx.doi.org/10.1038/bjc.2011.189; PMID: 21629244
   PubMed Web of Science ®Google Scholar
• Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 2008; 26:2292 - 8; http://dx.doi.org/10.1200/JCO.2007.13.3165; PMID: 18467720
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148 - 57; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332; PMID: 19276286
   PubMed Web of Science ®Google Scholar
• Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33:991 - 8; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208; PMID: 20948437
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73:539 - 49; http://dx.doi.org/10.1158/0008-5472.CAN-12-2325; PMID: 23108136
   PubMed Web of Science ®Google Scholar
• Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005; 15:199 - 204; http://dx.doi.org/10.1097/00008390-200506000-00009; PMID: 15917702
   PubMed Web of Science ®Google Scholar
• Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, et al. Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996; 14:1697 - 703; PMID: 8622090
   PubMed Web of Science ®Google Scholar
• Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002; 7:151 - 6; http://dx.doi.org/10.1080/13684730210002328; PMID: 14660055
   PubMed Web of Science ®Google Scholar
• Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007; 13:2422 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-06-1805; PMID: 17438101
   PubMed Web of Science ®Google Scholar
• Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, et al. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother 2012; 61:145 - 55; http://dx.doi.org/10.1007/s00262-011-1084-5; PMID: 21853302
   PubMed Web of Science ®Google Scholar